메뉴 건너뛰기




Volumn 39, Issue 12, 2012, Pages 2238-2246

Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-Year data from the REFLEX study

Author keywords

Biological therapy; CD20 antibody; Rheumatoid arthritis; Rituximab

Indexed keywords

ANTIINFECTIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

EID: 84870330803     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120573     Document Type: Article
Times cited : (63)

References (23)
  • 1
    • 33845592936 scopus 로고    scopus 로고
    • Rituximab: Novel B-cell depletion therapy for the treatment of rheumatoid arthritis
    • DOI 10.1517/14656566.7.18.2559
    • Dass S, Vital EM, Emery P. Rituximab: Novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2006;7:2559-70. (Pubitemid 44932458)
    • (2006) Expert Opinion on Pharmacotherapy , vol.7 , Issue.18 , pp. 2559-2570
    • Dass, S.1    Vital, E.M.2    Emery, P.3
  • 3
    • 58849088519 scopus 로고    scopus 로고
    • Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies
    • Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68:216-21.
    • (2009) Ann Rheum Dis , vol.68 , pp. 216-221
    • Keystone, E.1    Emery, P.2    Peterfy, C.G.3    Tak, P.P.4    Cohen, S.5    Genovese, M.C.6
  • 4
    • 77953715791 scopus 로고    scopus 로고
    • Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
    • Cohen SB, Keystone E, Genovese MC, Emery P, Peterfy C, Tak PP, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis 2010;69:1158-61.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1158-1161
    • Cohen, S.B.1    Keystone, E.2    Genovese, M.C.3    Emery, P.4    Peterfy, C.5    Tak, P.P.6
  • 5
    • 82755193559 scopus 로고    scopus 로고
    • Multiple courses of rituximab produce sustained efficacy in patients with rheumatoid arthritis with an inadequate response to one or more TNF inhibitors
    • abstract
    • Keystone EC, Fleischmann RM, Emery P, Dougados M, Williams S, Linnik MD, et al. Multiple courses of rituximab produce sustained efficacy in patients with rheumatoid arthritis with an inadequate response to one or more TNF inhibitors [abstract]. Arthritis Rheum 2010;62 Suppl:S133.
    • (2010) Arthritis Rheum , vol.62 , Issue.SUPPL.
    • Keystone, E.C.1    Fleischmann, R.M.2    Emery, P.3    Dougados, M.4    Williams, S.5    Linnik, M.D.6
  • 6
    • 84881479853 scopus 로고    scopus 로고
    • Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with focus on adverse events of interest in RA patients
    • in press
    • van Vollenhoven RF, Emery P, Bingham CO III, Keystone EC, Fleischmann R, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with focus on adverse events of interest in RA patients. Ann Rheum Dis [in press].
    • Ann Rheum Dis
    • Van Vollenhoven, R.F.1    Emery, P.2    Bingham III, C.O.3    Keystone, E.C.4    Fleischmann, R.5    Furst, D.E.6
  • 8
    • 77953696525 scopus 로고    scopus 로고
    • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
    • Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
    • (2010) Ann Rheum Dis , vol.69 , pp. 964-975
    • Smolen, J.S.1    Landewé, R.2    Breedveld, F.C.3    Dougados, M.4    Emery, P.5    Gaujoux-Viala, C.6
  • 9
    • 50249123223 scopus 로고    scopus 로고
    • Level of radiographic damage and radiographic progression are determinants of physical function: A longitudinal analysis of the TEMPO trial
    • van der Heijde D, Landewe R, van Vollenhoven R, Fatenejad S, Klareskog L. Level of radiographic damage and radiographic progression are determinants of physical function: A longitudinal analysis of the TEMPO trial. Ann Rheum Dis 2008;67:1267-70.
    • (2008) Ann Rheum Dis , vol.67 , pp. 1267-1270
    • Van Der Heijde, D.1    Landewe, R.2    Van Vollenhoven, R.3    Fatenejad, S.4    Klareskog, L.5
  • 12
    • 78149278597 scopus 로고    scopus 로고
    • Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER
    • van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewe R, Patra K, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010;37:2237-46.
    • (2010) J Rheumatol , vol.37 , pp. 2237-2246
    • Van Der Heijde, D.1    Breedveld, F.C.2    Kavanaugh, A.3    Keystone, E.C.4    Landewe, R.5    Patra, K.6
  • 13
    • 33646483031 scopus 로고    scopus 로고
    • The efficacy and safety of RTX in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial
    • Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of RTX in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
    • (2006) Arthritis Rheum , vol.54 , pp. 1390-1400
    • Emery, P.1    Fleischmann, R.2    Filipowicz-Sosnowska, A.3    Schechtman, J.4    Szczepanski, L.5    Kavanaugh, A.6
  • 14
    • 0031657148 scopus 로고    scopus 로고
    • Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs
    • DOI 10.1002/1529-0131(199809)41:9<1583::AID-ART8>3.0.CO;2-H
    • Genant HK, Jiang Y, Peterfy C, Lu Y, Redei J, Countryman PJ. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998;41:1583-90. (Pubitemid 28459916)
    • (1998) Arthritis and Rheumatism , vol.41 , Issue.9 , pp. 1583-1590
    • Genant, H.K.1    Jiang, Y.2    Peterfy, C.3    Lu, Y.4    Redei, J.5    Countryman, P.J.6
  • 15
    • 70350539709 scopus 로고    scopus 로고
    • Progressive multifocal leukoencephalopathy following RTX treatment in a patient with rheumatoid arthritis
    • Fleischmann RM. Progressive multifocal leukoencephalopathy following RTX treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009;60:3225-8.
    • (2009) Arthritis Rheum , vol.60 , pp. 3225-3228
    • Fleischmann, R.M.1
  • 17
    • 79951712039 scopus 로고    scopus 로고
    • Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
    • Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50:124-31.
    • (2011) Rheumatology , vol.50 , pp. 124-131
    • Galloway, J.B.1    Hyrich, K.L.2    Mercer, L.K.3    Dixon, W.G.4    Fu, B.5    Ustianowski, A.P.6
  • 18
    • 80053566154 scopus 로고    scopus 로고
    • Treatment benefit or survival of the fittest: What drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
    • Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: What drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011;70:1914-20.
    • (2011) Ann Rheum Dis , vol.70 , pp. 1914-1920
    • Strangfeld, A.1    Eveslage, M.2    Schneider, M.3    Bergerhausen, H.J.4    Klopsch, T.5    Zink, A.6
  • 20
    • 52149099504 scopus 로고    scopus 로고
    • IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial
    • Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
    • (2008) Ann Rheum Dis , vol.67 , pp. 1516-1523
    • Emery, P.1    Keystone, E.2    Tony, H.P.3    Cantagrel, A.4    Van Vollenhoven, R.5    Sanchez, A.6
  • 21
    • 80053571696 scopus 로고    scopus 로고
    • Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: Open-label extension of the ATTEST Study
    • Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: Open-label extension of the ATTEST Study. Ann Rheum Dis 2011;70:2003-7.
    • (2011) Ann Rheum Dis , vol.70 , pp. 2003-2007
    • Schiff, M.1    Keiserman, M.2    Codding, C.3    Songcharoen, S.4    Berman, A.5    Nayiager, S.6
  • 23
    • 82355169068 scopus 로고    scopus 로고
    • Retreatment with RTX based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: A retrospective pooled analysis
    • Emery P, Mease PJ, Rubbert-Roth A, Curtis JR, Muller-Ladner U, Gaylis NB, et al. Retreatment with RTX based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: A retrospective pooled analysis. Rheumatology 2011;50:2223-32.
    • (2011) Rheumatology , vol.50 , pp. 2223-2232
    • Emery, P.1    Mease, P.J.2    Rubbert-Roth, A.3    Curtis, J.R.4    Muller-Ladner, U.5    Gaylis, N.B.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.